Autifony Therapeutics

Autifony Therapeutics was founded in 2011 by Charles Large and Giuseppe Alvaro as a spin-off from GlaxoSmithKline, with the main focus on discovering and developing new pharmaceutical treatments for hearing disorders and age related hearing loss, as well as central nervous system disorders.

Autifony Therapeutics is currently not running any clinical trials related to hearing disorders or hearing loss.

Clinical Trials — Completed

Evaluating Possible Improvement in Speech and Hearing Tests After 28 Days of Dosing of the Study Drug AUT00063 Compared to Placebo (QuicKfire)

Condition: Hearing Loss; Hearing Impairment
Intervention: Drug: AUT00063; Drug: Placebo
Phase: Phase 2


Efficacy and Safety of AUT00063 Versus Placebo in Age-Related Hearing Loss

Condition: Age-Related Hearing Loss
Intervention: Drug: AUT00063; Drug: Placebo
Phase: Phase 2


Evaluating Possible Improvement in Tinnitus Severity After 28 Days Dosing of the Study Drug AUT00063 Compared to Placebo

Condition: Tinnitus, Subjective
Intervention: Drug: AUT00063; Drug: Placebo
Phase: Phase 2


Evaluating Possible Improvement in Tinnitus Severity After 28 Days Dosing of the Study Drug AUT00063 Compared to Placebo

Condition: Tinnitus, Subjective
Intervention: Drug: AUT00063; Drug: Placebo
Phase: Phase 2

RECENT NEWS ON AUTIFONY THERAPEUTICS

Nothing Found

Sorry, no posts matched your criteria

COMPANY OVERVIEW

Autifony Therapeutics

Locations: United Kingdom
Year Founded: 2011
CEO: Charles Large (Ph.D.)